ACETYLDIGITOXIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C43H66O14
Molecular Weight	806.9757
Optical Activity	UNSPECIFIED
Defined Stereocenters	20 / 20
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1O[C@H](C[C@H](OC(C)=O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C

InChI

InChIKey=HPMZBILYSWLILX-UMDUKNJSSA-N

InChI=1S/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C43H66O14
Molecular Weight	806.9757
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	20 / 20
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.medscape.com/viewarticle/842364

Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart failure; CHF). Digoxin has been in use for many years, but was not approved by the FDA for treatment of heart failure (HF) until the late 1990s. Another FDA indication for digoxin is atrial fibrillation (AF). Digoxin also has numerous off-label uses, such as in fetal tachycardia, supra-ventricular tachycardia, cor pulmonale, and pulmonary hypertension. Digitoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also has Para sympathomimetic properties. By increasing vagal tone in the sinoatrial and atrioventricular (AV) nodes, it slows the heart rate and AV nodal conduction.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 34 Target ID: CHEMBL2095186 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19751721	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart failure 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf	Primary		Approved 8583	CRYSTODIGIN Approved Use In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility
Chronic atrial fibrillation 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021648s004lbl.pdf	Diagnostic		Approved 8583	CRYSTODIGIN Approved Use In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1). In pediatric patients with heart failure, digoxin increases myocardial contractility

C_max

Value	Dose	Co-administered	Analyte	Population
1.76 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: ETORICOXIB	ETORICOXIB	DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.32 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
13.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: ETORICOXIB	ETORICOXIB	DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18823299/	0.25 mg 1 times / day steady-state, oral dose: 0.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DIGITOXIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
9.5 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, intravenous dose: 0.5 mg route of administration: Intravenous experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.4 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
9.7 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/914188/	0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered:	DIGITOXIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.1 mg 1 times / day multiple, oral Studied dose Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	healthy, 23 to 29 years Health Status: healthy Age Group: 23 to 29 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	Other AEs: Color blindness acquired... Other AEs: Color blindness acquired Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/
0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	Other AEs: Fatigue, Visual disorders NEC... Other AEs: Fatigue (53.1%) Visual disorders NEC (53.1%) Muscular weakness (45.8%) Nausea (45.2%) Anorexia (44.7%) Psychic disorder NOS (36.3%) Abdominal pain (36.3%) Dizziness (33%) Bad dreams (30.2%) Headache (25.1%) Diarrhoea (22.9%) Vomiting (22.3%) Pain retrosternal (5%) Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/

AEs

AE	Significance	Dose	Population
Color blindness acquired		0.1 mg 1 times / day multiple, oral Studied dose Dose: 0.1 mg, 1 times / day Route: oral Route: multiple Dose: 0.1 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/	healthy, 23 to 29 years Health Status: healthy Age Group: 23 to 29 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/7816418/
Vomiting	22.3%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Diarrhoea	22.9%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Headache	25.1%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Bad dreams	30.2%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Dizziness	33%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Abdominal pain	36.3%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Psychic disorder NOS	36.3%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Anorexia	44.7%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Nausea	45.2%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Muscular weakness	45.8%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Pain retrosternal	5%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Fatigue	53.1%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/
Visual disorders NEC	53.1%	0.2 mg 2 times / day multiple, oral Studied dose Dose: 0.2 mg, 2 times / day Route: oral Route: multiple Dose: 0.2 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/5273245/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 OATP1B3 961	P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24754247/	yes [IC50 14.2 uM]
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24754247/	yes [IC50 36 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21316177/; https://pubmed.ncbi.nlm.nih.gov/18080812/; https://pubmed.ncbi.nlm.nih.gov/11284449/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/17095614/

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA003PFS	https://www.aablocks.com/goods/Goods/detail?id=AA003PFS
Aaron Chemicals	AR003Q7K	http://www.aaronchem.com/71-63-6
Acorn PharmaTech	ACN-035831	http://www.acornpharmatech.com/
AHH Chemical co.,ltd	MT-50144	http://www.ahhchemical.com/product/MT-50144.html
AK Scientific, Inc. (AKSCI)	Y0070	http://www.aksci.com/item_detail.php?cat=Y0070
Alfa Chemistry	AP71636-A	https://reagents.alfa-chemistry.com/product/digitoxin-solution-cas-71-63-6-15505.html
Alfa Chemistry	AP71636-B	https://reagents.alfa-chemistry.com/product/digitoxin-cas-71-63-6-15506.html
Aurora Fine Chemicals LLC	A17.877.985	http://online.aurorafinechemicals.com/info?ID=A17.877.985
Aurora Fine Chemicals LLC	K05.570.447	http://online.aurorafinechemicals.com/info?ID=K05.570.447
BioSynth	Q-100791	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100791.html
Chem Scene	CS-5502	http://www.chemscene.com/71-63-6.html
Chemenu	CM110200	http://www.chemenu.com/products/CM110200
ChemFaces	CFN98535	http://www.chemfaces.com/natural/Digitoxin-CFN98535.html
ChemMol	99138549	http://www.chemmol.com/chemmol/99138549.html
Chemspace	CSSS00026968232	https://chem-space.com/CSSS00026968232
DC Chemicals	DC37933	http://www.dcchemicals.com//product_show-Digitoxin.html
Enamine	Z1558290128	https://www.enaminestore.com/catalog/Z1558290128
eNovation Chemicals	D659640	https://www.enovationchem.com/ProductDetails.asp?ProductID=D659640
Glentham Life Sciences	GC5627	http://www.glentham.com/products/product/GC5627/
iChemical	EBD27273	http://www.ichemical.com/products/71-63-6.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01343864	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343864
LGC Standards	DRE-A12633800AL-100	https://www.lgcstandards.com/US/en/p/DRE-A12633800AL-100
LGC Standards	DRE-C12633800	https://www.lgcstandards.com/US/en/p/DRE-C12633800
mcule	MCULE-8291336831	https://mcule.com/MCULE-8291336831/
mcule	MCULE-9783596421	https://mcule.com/MCULE-9783596421/
MedChem Express	HY-B1357	https://www.medchemexpress.com/Digitoxin.html
MolPort	MolPort-001-742-606	https://www.molport.com/shop/molecule-link/MolPort-001-742-606
MuseChem	I004671	https://www.musechem.com/product/I004671.html
MuseChem	M050845	https://www.musechem.com/product/M050845.html
OChem	11973	http://www.ocheminc.com/index.php?act=psearch&pid=071D636
R&D Chemicals	825	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=7705
Sigma-Aldrich	1199002_USP	https://www.sigmaaldrich.com/catalog/product/usp/1199002?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP855_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp855?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	D1800000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/d1800000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	D5878_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/d5878?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S526083	http://www.smolecule.com/products/s526083
TCI (Tokyo Chemical Industry)	D0542	http://www.tcichemicals.com/eshop/en/us/commodity/D0542/index.html
THE BioTek	bt-264686	https://www.thebiotek.com/product/inhibitors/bt-264686

PubMed

Title	Date	PubMed
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.	2015-06	25752796
A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.	2014-04	24275119
Interaction of digitalis-like compounds with p-glycoprotein.	2013-02	23104431
Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents.	2013	24124520
Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells.	2012-01-01	22037315
Antiherpes activity of glucoevatromonoside, a cardenolide isolated from a Brazilian cultivar of Digitalis lanata.	2011-10	21763352
Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: Therapeutic implications for the treatment of atherosclerosis?	2009-10	19446813
Heart failure drug digitoxin induces calcium uptake into cells by forming transmembrane calcium channels.	2008-02-19	18272488
Iatrogenic sick sinus syndrome.	2007-05	17460324
Bidirectional ventricular tachycardia due to digitalis intoxication.	2005-02	15674736
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells.	2004-05-18	15136726
Posterior encephalopathy with vasospasm: MRI and angiography.	2003-12	14574425
Bidirectional tachycardia: two cases and a review.	2002-08	12145041
Adverse drug reaction monitoring--digitoxin overdosage in the elderly.	2001-08	11515708
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells.	2001-06	11395576
Digitoxin medication and cancer; case control and internal dose-response studies.	2001	11532201
Treatment of congestive heart failure--current status of use of digitoxin.	2001	11525233
Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?	2000-10	11051385
Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin.	2000-09	11016824
Synthesis of 20-hydroxy-, 20-amino-, and 20-nitro-14-hydroxy-21-nor-5 beta,14 beta-pregnane C-3 glycosides and related derivatives: structure-activity relationships of pregnanes that bind to the digitalis receptor.	1993-01-08	8421289
[Digitoxin-induced thrombocytopenia].	1993	8212711
Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.	1992	1469187
Effect of digitoxin on cardiac arrhythmias in hemodialysis patients.	1987-11-16	2447325
Effect of long-term administration of digoxin on exercise performance in chronic airflow obstruction.	1985-04	4018179
Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat.	1985	2436403
[Digitoxin poisoning: reversing ventricular fibrillation with Fab fragments of anti-digoxin antibody].	1982-12-25	7162976
Effect of age, clonidine or propranolol on behavioral toxicity induced with digitoxin in mice.	1982-09	7146044
Reversal of digitalis-induced mesenteric vasospasm by sodium nitroprusside.	1982-02	7059269
Effects of atropine on the cardiac arrest induced by propranolol and digitoxin in dogs.	1982	7119638
Digitalis delirium: a reminder.	1980-03	7361148
Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.	1977-12	914999
Hypotensive and antiarrhythmic effects of a new alkaloid, the 13-hydroxylupanine-2-pyrrolcarbonic acid ester, from the Madagascan plant Cadia ellisiana.	1976	11808
Transient global amnesia associated with cardiac arrhythmia and digitalis intoxication.	1975-09-01	1179459
Effect of microsomal enzyme inducers on the biliary excretion of cardiac glycosides.	1974-11	4418514
His bundle electrocardiography during bidirectional tachycardia.	1973-07	4781244
The clinical value of serum digitalis glycoside concentrations in the evaluation of drug toxicity.	1971-07-06	4255107
Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication.	1971-03	5569832
Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse.	1971-01	5130149
[Acute digitalic poisoning].	1970-02	5447167
[Spironolactone protection against experimental cardiopathy due to digitoxin, disodium phosphate and oil].	1970-02	4909201
Digitoxin induced cardiac necrosis and its inhibition.	1969	5384065
Atrial dissociation due to digitalis toxicity.	1968-06	5654317
[On the treatment of the digitalis-induced atrial tachycardia with AV conduction disorder. Experiences with sodium-magnesium aspartate].	1968-03-29	5727264
Influence of drugs, implanted into the hypothalamus, on the water consumption of rats.	1968-01	5643946
[Cardiac arrhythmia in old age caused by digitalis intoxication].	1967-04-27	6022657

Patents

Sample Use Guides

In Vivo Use Guide

Age Oral Loading Dose, mcg/kg Premature: 20 - 30; Full-Term 25 - 35; 1 to 24 months 35 - 60; 2 to 5 years 30 - 45; 5 to 10 years 20 - 35; Over 10 years 10 - 15

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:04:30 GMT 2025` Edited by `admin` on `Mon Mar 31 18:04:30 GMT 2025`
Record UNII	0ZV4Q4L2FU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACETYLDIGITOXINS .ALPHA.-FORM

Preferred Name

English

ACETYLDIGITOXIN

Official Name

English

ACETYLDIGITOXIN [MART.]

Common Name

English

(3.BETA.,5.BETA.)-3-((O-3-O-ACETYL-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-14-HYDROXYCARD-20(22)-ENOLIDE

Common Name

English

Acetyldigitoxin [WHO-DD]

Common Name

English

ACETYLDIGITOXINS .ALPHA.-FORM [MI]

Common Name

English

acetyldigitoxin [INN]

Common Name

English

ACYLANID

Brand Name

English

ACETYLDIGITOXIN [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC01AA01